ホスファチジルイノシトール-4、5-ビスホスフェート3-キナーゼ触媒サブユニットガンマアイソフォーム治療薬市場:パイプラインレビュー(2019年下半期)

◆英語タイトル:Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Gamma Isoform - Pipeline Review, H2 2019
◆商品コード:GDATA20MY0483
◆発行会社(リサーチ会社):Global Markets Direct
◆発行日:2019年12月27日
◆ページ数:127
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD3,500 ⇒換算¥378,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD7,000 ⇒換算¥756,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD10,500 ⇒換算¥1,134,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobal Markets Direct社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Global Markets Direct社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

【レポートの概要】

Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Gamma Isoform – Pipeline Review, H2 2019
Summary

According to the recently published report ‘Phosphatidylinositol 4,5 Bisphosphate 3 – Pipeline Review, H2 2019′; Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Gamma Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Gamma or Phosphoinositide 3 Kinase Catalytic Gamma Polypeptide or Serine/Threonine Protein Kinase PIK3CG or p120 PI3K or PIK3CG or EC 2.7.11.1 or EC 2.7.1.153) pipeline Target constitutes close to 21 molecules. Out of which approximately 20 molecules are developed by companies and remaining by the universities/institutes.

Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Gamma Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Gamma or Phosphoinositide 3 Kinase Catalytic Gamma Polypeptide or Serine/Threonine Protein Kinase PIK3CG or p120 PI3K or PIK3CG or EC 2.7.11.1 or EC 2.7.1.153) – Phosphatidylinositol-4, 5-bisphosphate 3-kinase catalytic subunit gamma isoform is an enzyme encoded by the PIK3CG gene. It plays a key role by recruiting PH domain-containing proteins to the membrane, including AKT1 and PDPK1, activating signaling cascades involved in cell growth, survival, proliferation, motility and morphology. It is involved in immune, inflammatory and allergic responses. It modulates leukocyte chemotaxis to inflammatory sites and in response to chemoattractant agents. It regulates T-lymphocyte proliferation and cytokine production.

The report ‘Phosphatidylinositol 4,5 Bisphosphate 3 – Pipeline Review, H2 2019′ outlays comprehensive information on the Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Gamma Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Gamma or Phosphoinositide 3 Kinase Catalytic Gamma Polypeptide or Serine/Threonine Protein Kinase PIK3CG or p120 PI3K or PIK3CG or EC 2.7.11.1 or EC 2.7.1.153) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Gamma Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Gamma or Phosphoinositide 3 Kinase Catalytic Gamma Polypeptide or Serine/Threonine Protein Kinase PIK3CG or p120 PI3K or PIK3CG or EC 2.7.11.1 or EC 2.7.1.153) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Pre-Registration, Phase II, Phase I, Preclinical and Discovery stages are 1, 3, 1, 13 and 2 respectively.

Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively. Report covers products from therapy areas Oncology, Respiratory, Immunology, Hematological Disorders, Infectious Disease and Undisclosed which include indications Cutaneous T-Cell Lymphoma, Solid Tumor, Chronic Obstructive Pulmonary Disease (COPD), Colon Cancer, Ovarian Cancer, Peripheral T-Cell Lymphomas (PTCL), Refractory Chronic Lymphocytic Leukemia (CLL), Relapsed Chronic Lymphocytic Leukemia (CLL), Asthma, Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, Head And Neck Cancer Squamous Cell Carcinoma, Lung Cancer, Lymphoma, Multiple Myeloma (Kahler Disease), Pancreatic Cancer, Renal Cell Carcinoma, T-Cell Lymphomas, Triple-Negative Breast Cancer (TNBC), Adrenocortical Carcinoma (Adrenal Cortex Cancer), Allergic Asthma, Anaplastic Large Cell Lymphoma (ALCL), Angioimmunoblastic T-Cell Lymphoma (AITL)/Immunoblastic Lymphadenopathy, Bladder Cancer, Breast Cancer, Chronic Lymphocytic Leukemia (CLL), Colorectal Cancer, Cystic Fibrosis, Gallbladder Cancer, Gastric Cancer, Glioblastoma Multiforme (GBM), Human Immunodeficiency Virus (HIV) Infections (AIDS), Idiopathic Pulmonary Fibrosis, Inflammation, Malignant Mesothelioma, Marginal Zone B-cell Lymphoma, Metastatic Melanoma, Metastatic Renal Cell Carcinoma, Metastatic Transitional (Urothelial) Tract Cancer, Natural Killer Cell Lymphomas, Neuroblastoma, Neutrophilia, Non-Small Cell Lung Cancer, Primary CNS Lymphoma, Recurrent Head And Neck Cancer Squamous Cell Carcinoma, Rheumatoid Arthritis, T-Cell Acute Lymphocytic Leukemia (T-Cell Acute Lymphoblastic Leukaemia), Unspecified and Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma).

Scope

- The report provides a snapshot of the global therapeutic landscape for Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Gamma Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Gamma or Phosphoinositide 3 Kinase Catalytic Gamma Polypeptide or Serine/Threonine Protein Kinase PIK3CG or p120 PI3K or PIK3CG or EC 2.7.11.1 or EC 2.7.1.153)
- The report reviews Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Gamma Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Gamma or Phosphoinositide 3 Kinase Catalytic Gamma Polypeptide or Serine/Threonine Protein Kinase PIK3CG or p120 PI3K or PIK3CG or EC 2.7.11.1 or EC 2.7.1.153) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Gamma Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Gamma or Phosphoinositide 3 Kinase Catalytic Gamma Polypeptide or Serine/Threonine Protein Kinase PIK3CG or p120 PI3K or PIK3CG or EC 2.7.11.1 or EC 2.7.1.153) targeted therapeutics and enlists all their major and minor projects
- The report assesses Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Gamma Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Gamma or Phosphoinositide 3 Kinase Catalytic Gamma Polypeptide or Serine/Threonine Protein Kinase PIK3CG or p120 PI3K or PIK3CG or EC 2.7.11.1 or EC 2.7.1.153) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Gamma Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Gamma or Phosphoinositide 3 Kinase Catalytic Gamma Polypeptide or Serine/Threonine Protein Kinase PIK3CG or p120 PI3K or PIK3CG or EC 2.7.11.1 or EC 2.7.1.153) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Gamma Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Gamma or Phosphoinositide 3 Kinase Catalytic Gamma Polypeptide or Serine/Threonine Protein Kinase PIK3CG or p120 PI3K or PIK3CG or EC 2.7.11.1 or EC 2.7.1.153)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Gamma Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Gamma or Phosphoinositide 3 Kinase Catalytic Gamma Polypeptide or Serine/Threonine Protein Kinase PIK3CG or p120 PI3K or PIK3CG or EC 2.7.11.1 or EC 2.7.1.153) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

【レポートの目次】

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Gamma Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Gamma or Phosphoinositide 3 Kinase Catalytic Gamma Polypeptide or Serine/Threonine Protein Kinase PIK3CG or p120 PI3K or PIK3CG or EC 2.7.11.1 or EC 2.7.1.153) – Overview
Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Gamma Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Gamma or Phosphoinositide 3 Kinase Catalytic Gamma Polypeptide or Serine/Threonine Protein Kinase PIK3CG or p120 PI3K or PIK3CG or EC 2.7.11.1 or EC 2.7.1.153) – Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Gamma Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Gamma or Phosphoinositide 3 Kinase Catalytic Gamma Polypeptide or Serine/Threonine Protein Kinase PIK3CG or p120 PI3K or PIK3CG or EC 2.7.11.1 or EC 2.7.1.153) – Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Gamma Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Gamma or Phosphoinositide 3 Kinase Catalytic Gamma Polypeptide or Serine/Threonine Protein Kinase PIK3CG or p120 PI3K or PIK3CG or EC 2.7.11.1 or EC 2.7.1.153) – Companies Involved in Therapeutics Development
Applied Therapeutics Inc
Arcus Biosciences Inc
AstraZeneca Plc
BioMed Valley Discoveries Inc
Chia Tai Tianqing Pharmaceutical Group Co Ltd.
Hutchison MediPharma Ltd
Infinity Pharmaceuticals Inc
Kither Biotech Srl
Novartis AG
PIQUR Therapeutics AG
Rhizen Pharmaceuticals SA
Sichuan Sinovation Bio-technology Co Ltd
SignalRx Pharmaceuticals Inc
Sphaera Pharma Pte Ltd
Verastem Inc
Vertex Pharmaceuticals Inc
Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Gamma Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Gamma or Phosphoinositide 3 Kinase Catalytic Gamma Polypeptide or Serine/Threonine Protein Kinase PIK3CG or p120 PI3K or PIK3CG or EC 2.7.11.1 or EC 2.7.1.153) – Drug Profiles
AB-610 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AT-104 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AZD-8154 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
bimiralisib – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BVD-723 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CL-27 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
duvelisib – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IPI-549 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KIT-2014 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PQR-514 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SF-2523 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit PI3K Delta and PI3K Gamma for Rheumatoid Arthritis – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit PI3K Gamma for Unspecified Indication – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit PIK3CG for Chronic Obstructive Pulmonary Disease and Neutrophilia – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit Pan PI3K for Ovarian Cancer – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit PIK3CA and PIK3CG for Solid Tumors – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit PIK3CD and PIK3CG for Oncology – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SN-202 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SPR-965 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tenalisib – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
WX-008 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Gamma Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Gamma or Phosphoinositide 3 Kinase Catalytic Gamma Polypeptide or Serine/Threonine Protein Kinase PIK3CG or p120 PI3K or PIK3CG or EC 2.7.11.1 or EC 2.7.1.153) – Dormant Products
Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Gamma Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Gamma or Phosphoinositide 3 Kinase Catalytic Gamma Polypeptide or Serine/Threonine Protein Kinase PIK3CG or p120 PI3K or PIK3CG or EC 2.7.11.1 or EC 2.7.1.153) – Discontinued Products
Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Gamma Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Gamma or Phosphoinositide 3 Kinase Catalytic Gamma Polypeptide or Serine/Threonine Protein Kinase PIK3CG or p120 PI3K or PIK3CG or EC 2.7.11.1 or EC 2.7.1.153) – Product Development Milestones
Featured News & Press Releases
Dec 07, 2019: Verastem oncology presents phase 2 PRIMO study data evaluating duvelisib in relapsed or refractory peripheral T-Cell lymphoma at the american society of hematology 2019 annual meeting
Nov 25, 2019: Verastem Oncology announces submission of a marketing authorization application to the European Medicines Agency for COPIKTRA (duvelisib)
Nov 06, 2019: Verastem Oncology to phase 2 PRIMO study data evaluating duvelisib in relapsed or refractory peripheral t-cell lymphoma at the American Society of Hematology 2019 Annual Meeting
Oct 23, 2019: Verastem Oncology announces COPIKTRA (Duvelisib) presentations at the Lymphoma & Myeloma 2019 International Congress
Oct 07, 2019: Verastem Oncology announces dosing of first patient in Vakult Honsha Japanese bridging study evaluating Copiktra (Duvelisib) in patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma
Oct 03, 2019: Verastem Oncology receives Orphan Drug Designation from FDA for COPIKTRA for the treatment of T-Cell Lymphoma
Oct 03, 2019: Verastem Oncology presents new preclinical Duvelisib data at the 5th International Conference on new concepts in lymphoid malignancies
Sep 25, 2019: AstraZeneca to present AZD8154 data at ERS International Congress
Sep 20, 2019: Verastem Oncology announces COPIKTRA (Duvelisib) presentations at the 18th Annual International Workshop on Chronic Lymphocytic Leukemia
Sep 04, 2019: Infinity Pharmaceuticals announces the initiation of two clinical trials evaluating IPI-549 in novel Triple Combination Therapies for the treatment of Solid Tumors
Sep 03, 2019: Verastem Oncology announces COPIKTRA (Duvelisib) presentations at the Society of Hematologic Oncology 2019 Annual Meeting
Aug 22, 2019: Infinity Pharmaceuticals announces transition of Samuel Agresta, M.D., from chief medical officer to board of directors
Jun 21, 2019: Verastem Oncology presents COPIKTRA (Duvelisib) data in peripheral T-cell lymphoma at the 2019 International Conference on Malignant Lymphoma
Jun 17, 2019: Verastem Oncology presents COPIKTRA (Duvelisib) data at the European Hematology Association 2019 Annual Meeting
May 15, 2019: Verastem Oncology to present new COPIKTRA (Duvelisib) dose modification data from patients treated in the phase 3 DUO study
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Indications, H2 2019
Number of Products under Development by Indications, H2 2019 (Contd..1), H2 2019
Number of Products under Development by Indications, H2 2019 (Contd..2), H2 2019
Number of Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Products under Development by Companies, H2 2019 (Contd..2), H2 2019
Products under Development by Companies, H2 2019 (Contd..3), H2 2019
Products under Development by Companies, H2 2019 (Contd..4), H2 2019
Number of Products under Investigation by Universities/Institutes, H2 2019
Products under Investigation by Universities/Institutes, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Pipeline by Applied Therapeutics Inc, H2 2019
Pipeline by Arcus Biosciences Inc, H2 2019
Pipeline by AstraZeneca Plc, H2 2019
Pipeline by BioMed Valley Discoveries Inc, H2 2019
Pipeline by Chia Tai Tianqing Pharmaceutical Group Co Ltd., H2 2019
Pipeline by Hutchison MediPharma Ltd, H2 2019
Pipeline by Infinity Pharmaceuticals Inc, H2 2019
Pipeline by Kither Biotech Srl, H2 2019
Pipeline by Novartis AG, H2 2019
Pipeline by PIQUR Therapeutics AG, H2 2019
Pipeline by Rhizen Pharmaceuticals SA, H2 2019
Pipeline by Sichuan Sinovation Bio-technology Co Ltd, H2 2019
Pipeline by SignalRx Pharmaceuticals Inc, H2 2019
Pipeline by Sphaera Pharma Pte Ltd, H2 2019
Pipeline by Verastem Inc, H2 2019
Pipeline by Vertex Pharmaceuticals Inc, H2 2019
Dormant Products, H2 2019
Dormant Products, H2 2019 (Contd..1), H2 2019
Discontinued Products, H2 2019

【掲載企業】

Applied Therapeutics Inc
Arcus Biosciences Inc
AstraZeneca Plc
BioMed Valley Discoveries Inc
Chia Tai Tianqing Pharmaceutical Group Co Ltd.
Hutchison MediPharma Ltd
Infinity Pharmaceuticals Inc
Kither Biotech Srl
Novartis AG
PIQUR Therapeutics AG
Rhizen Pharmaceuticals SA
Sichuan Sinovation Bio-technology Co Ltd
SignalRx Pharmaceuticals Inc
Sphaera Pharma Pte Ltd
Verastem Inc
Vertex Pharmaceuticals Inc

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[ホスファチジルイノシトール-4、5-ビスホスフェート3-キナーゼ触媒サブユニットガンマアイソフォーム治療薬市場:パイプラインレビュー(2019年下半期)]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆